S1 Data - by Perumal Vivekanandhan (4863484)

“…<i>eugeniae</i> at 24 hours post-treatment. The LC₅₀ values were 634.747 mg/L for <i>A</i>. …”

Functional linear modeling (FLM) of activity data following intramuscular administration of either 0.1 mL saline, 0.4 mg/kg meloxicam, 2.2 mg/kg flunixin or 3.0 mg/kg ketoprofen in... by Emma Nixon (11772946)

Total plasma cortisol concentration over time following intramuscular administration of either 0.1 mL saline, 0.4 mg/kg meloxicam, 2.2 mg/kg flunixin or 3.0 mg/kg ketoprofen in 6-d... by Emma Nixon (11772946)

S1 Data - by Chiara E. Hampton (16484687)

Subjects:

FTY720 potentiated the activity of cisplatin. by Laura L. Stafman (6577184)

Salivary indicator changes after acid stimulation in HCG and MG. by Ye Huang (1482538)

Decreased osteoclast formation by LDH-A or LDH-B depletion. by Heejin Ahn (3173670)

Fig 2 - by Nida Mansoora (11648641)

Fig 3 - by Nida Mansoora (11648641)

Fig 4 - by Nida Mansoora (11648641)

Fig 1 - by Nida Mansoora (11648641)

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Propofol increased the number of the hippocampal pyramidal neurons and decreased the expression of the LC3-II protein and the number of lysosomes and autophagosomes in the ischemic... by Derong Cui (326839)

“…<p>I/R was induced by 2-vessel occlusion. Propofol 10, 50, or 100 mg/kg was administrated intraperitoneally and 3-MA (600 nM) was administered intracerebroventricularly 10 min after the onset of ischemia. (1) Sham-operated group (control group, Cont); (2) I/R group; (3) I/R+ 3-MA 600 nmol group; (4) I/R + propofol 10 mg/kg group; (5) I/R + propofol 50 mg/kg group; (6) I/R + propofol 100 mg/kg group; (7) I/R + vehicle (intralipid, 100 mg/kg) group. …”

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)